LifeVantage (LFVN) is a $100M direct-selling supplement company, down 67% over twelve months. On April 16, an 8-K confirmed Terrence Moorehead — who ran peer Nature's Sunshine (NATR) from 2018 to 2025 — as CEO effective August 5. Shorts hold 36.6% of float, positioned for an MED-style collapse. NATR's own segment data, which the short thesis hasn't synthesized, suggests shorts have misread Moorehead's track record.

What the filing says

Item 5.02 formalizes three moves. Fife retires April 30. Director Michael Beindorff — age 74, a real estate investor — serves as interim CEO May 1 through August 4 at $45,833/month. Moorehead assumes the role permanently on August 5. His compensation includes a $7.5M performance stock unit grant tied to revenue and EBITDA margin targets. Personal capital anchored to LFVN's numbers.

What the market thinks

Forward P/E 7.6x versus 10x peer median (HLF, NUS, USNA) and NATR at 15x — a 24% execution-risk discount. Q2 FY2026 revenue was $48.9M, down 27.8% YoY, as the MindBody GLP-1 System lapped its October 2024 launch. FY26 guidance: $185–200M (vs FY25's $228.5M). Cash $10.2M, no debt, 4.12% dividend maintained, $60M buyback authorization unused (60% of market cap).

Positioning contradicts itself. Short float 36.6% says MED thesis. Options P/C 0.15 says smart money is long. IV is at the 107th percentile. Two analysts carry Buys at an $8 target. Three directors have bought shares on the open market at or near 52-week lows since February, including Judd's $152K clip on March 2.

Our read of market-implied P(turnaround), inferred from the multiple discount and short positioning: 25–35%. Our estimate: 50–60%. Edge 20–30 points.

Why the gap exists

Moorehead's NATR track record is public: +45% revenue, +190% EBITDA, 2018–2025. The short thesis implicitly assumes this was GLP-1 tailwind — that Moorehead rode the same weight-loss wave that lifted LFVN's MindBody launch. Primary sources contradict the assumption.

NATR's 10-K segment disclosures:

• 2016 (pre-Moorehead): weight management was 8.3% of revenue, $28.5M
• FY2025: weight management was 3.7% of revenue, $17.9M

Weight management shrank 37% in absolute dollars while total revenue grew 41% from $341M to $480M. The category that would have captured GLP-1 tailwind contracted under Moorehead's tenure.

Six NATR earnings transcripts (Q3 2024 through Q4 2025) contain zero mentions by Moorehead of "GLP-1," "Ozempic," "Wegovy," or "weight loss" as a growth driver. What he attributes growth to: digital platform +19% (double industry rate), Subscribe & Thrive autoship reaching 53% of DTC revenue, Japan +27%, China +36%, Korea +12%, Central Europe +15%, nutritional practitioner channel expansion. Network, digital, geographic. Transferable.

LFVN is actually the GLP-1 story that shorts attribute to NATR. LFVN's FY2025 10-K credits the MindBody launch with $40.8M of revenue — without it, the company was flat. The Q2 FY2026 collapse is product-cycle failure, not network death. Moorehead's job is to rebuild network and digital infrastructure. That is what he did at NATR.

Peer FY22–FY25 revenue: NATR +14%, HLF -3%, NUS -33%, USNA -14%, MED -76%, LFVN +11% (entirely MindBody). MED is the GLP-1 displacement victim. The spread is execution quality, not sector collapse. LFVN is the worst performer in the group, about to be run by the operator from the best.

Risks (ranked)

1. Protandim product-market fit. Moorehead's skill is network, digital, and international — not product. NATR had six categories; LFVN is Protandim-concentrated. If the flagship can't support a rebuild absent a GLP-1-adjacent product pull, even Moorehead can't fix it.
2. MED trajectory. Q3 FY2026 worse than Q2's -27.8% means the network is past saving before the jockey arrives. Dividend likely follows.
3. Four-month leadership gap. May 1 through August 4 has no operational CEO, with Q3 earnings printing in the middle of the vacuum.

Catalysts

• May 12 (T+26d): Q3 FY2026. Revenue decline trajectory, dividend maintenance, buyback pace, consultant count trend.
• August 5 (T+111d): Moorehead starts. Early strategic priorities and any NATR lieutenants he hires.
• October–November: Q1 FY2027, first Moorehead-influenced quarter.
• May 2027: Q3 FY2027 laps Q3 FY2026's -27.8% base — the first realistic positive YoY print.

What would change our mind

• Dividend cut.
• Q3 FY2026 revenue decline worse than -27.8%.
• Moorehead withdraws, or terms renegotiated weaker.
• Zero buyback deployment through FY2026.
• Active consultant count -40% YoY or worse if disclosed.

Forward Sharpe on this thesis is approximately 0.65 (α ≈ 34% over 12 months, σ_idio ≈ 53%).

Evidence